For anyone in Birr looking to source CJC-1295, the first thing to know is that this compound is distributed via specialist online vendors. What this means for Birr researchers is that geography is secondary to your ability to verify analytical documentation — and those quality checks are within reach of all serious researchers. A credible CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. The sections below cover what Birr researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Birr comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Before assessing any particular supplier, establish a quality benchmark — so you can recognise whether a vendor meets it. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Positive vendor signals beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and shipping with desiccant and appropriate cold protection. The powdered lyophilised form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Birr
COA-verified · International tracking · Research grade
All use of CJC-1295 in Birr or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Proper handling of CJC-1295 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and temperature control throughout the entire workflow. Bacterial endotoxin contamination is the greatest safety hazard specific to research peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
